ImmuDyn

Drug Profile

ImmuDyn

Latest Information Update: 09 Mar 2006

Price : $50

At a glance

  • Originator Able Laboratories
  • Class Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Mar 2006 Discontinued - Clinical-Phase-Unknown for HIV infections treatment (SC)
  • 08 Feb 2001 No-Development-Reported for Immune thrombocytopenic purpura in USA (SC)
  • 08 Feb 2001 No-Development-Reported for Immune thrombocytopenic purpura in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top